India's vaccine market to be worth $3.07 billion by 2025

12 May 2023

The Indian vaccine market has carved a niche for itself at the global level and is anticipated to reach a valuation of $3.07 billion by 2025, according to Minister of State for Science and Technology Jitendra Singh, who was on an official visit to the UK.

Seeking collaboration between India and the UK in the areas of biotech start-ups and vaccine development, the minister said India has developed four indigenous vaccines in just two years.

Mr Singh held a series of meetings with the ministers in the UK government. During a tour of the London Science Museum, Singh said the world is increasingly aware of India's superlative capabilities in preventive healthcare.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK